SAN ANTONIO – The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio announced today that Francis J. Giles, MD, MB, FRCPI, FRCPath, has been honored as the recipient of the Medtronic Award at the National University of Ireland Galway Alumni Awards Gala. The Medtronic Award for Healthcare and Medical Science acknowledges Dr. Giles’ demonstrated contribution to the field of health care and medical science.
Dr. Giles is the deputy director of the CTRC and director of The Institute for Drug Development, CTRC’s internationally acclaimed oncology drug development program. He also serves concurrently as the chief of the Division of Hematology and Medical Oncology at the Health Science Center. Dr. Giles, who received his medical training at the National University of Ireland Galway, has focused his clinical and research efforts on providing therapy for patients suffering from treatment-resistant or refractory cancer. His interests include lymphomas, multiple myeloma, developmental therapeutics, stem cell transplantation and leukemias. He has pioneered the use of many agents that are now in regular use as targeted therapies for patients with cancer.
“I am delighted and honored to be a recipient of this award,” Dr. Giles said. “I am grateful to accept this award on behalf of the enormous number of people in a wide variety of preclinical and clinical disciplines who are working so hard around the world to eliminate cancer.”
The NUI Galway’s ninth annual Gala Banquet took place at the Radisson SAS Hotel in Galway, Ireland, on Saturday, March 1, 2008.
The Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio Located in San Antonio, Texas, The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio is one of the nation’s leading academic research and treatment centers, serving more than 4.4 million people in the high-growth corridor of Central and South Texas including Austin, San Antonio, Laredo and the Rio Grande Valley. CTRC is one of a few elite cancer centers in the country to be named a National Cancer Institute (NCI) Designated Cancer Center and is one of only three in Texas. CTRC handles more than 120,000 patient visits each year and is a world leader in developing new drugs to treat cancer. The CTRC Institute for Drug Development (IDD) is internationally recognized for conducting the largest oncology Phase I clinical drug trials program in the world, and participated in the clinical and/or preclinical development of many of the cancer drugs approved by the U.S. Food & Drug Administration. For more information, visit our Web site at www.ctrc.uthscsa.edu.